Syndrome News and Research

RSS

Amgen to present updated data on Nplate at the 2009 ASH meeting

Amgen Inc. today announced that it will present updated long-term safety and efficacy data for Nplate® (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura (ITP). Additionally, Amgen will present the first Nplate study in a pediatric setting as well as in patients with myelodysplastic syndromes (MDS) at the 2009 American Society of Hematology (ASH) Annual Meeting and Exposition (Dec. 5 - 8, 2009).

1 Dec 2009

BioMarin Pharmaceutical receives FDA orphan drug designation for 3,4-DAP

BioMarin Pharmaceutical Inc. announced today that the Food and Drug Administration (FDA) has granted orphan drug designation for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS). 3,4-DAP has previously received orphan drug designation in the E.U.

30 Nov 2009

Additional data on lubiprostone presented at the GASTRO 2009 UEGF/WCOG meeting

Sucampo Pharma Europe, Ltd., and Sucampo Pharma Americas, Inc., subsidiaries of Sucampo Pharmaceuticals, Inc., today presented additional clinical data for lubiprostone (Amitiza®) at GASTRO 2009 UEGF/WCOG, the joint meeting of the United European Gastroenterology Federation (UEGF), the World Gastroenterology Organisation (WGO), the World Organisation of Digestive Endoscopy (OMED) and the British Society of Gastroenterology (BSG), in London.

25 Nov 2009

Health watch: When you eat just as vital to what you eat

When you eat may be just as vital to your health as what you eat, found researchers at the Salk Institute for Biological Studies. Their experiments in mice revealed that the daily waxing and waning of thousands of genes in the liver—the body's metabolic clearinghouse—is mostly controlled by food intake and not by the body's circadian clock as conventional wisdom had it.

25 Nov 2009

Comparison study finds no significant differences in post-transplant survival rates of NASH and ETOH groups

Researchers at the University of Miami School of Medicine compared the outcomes of cirrhotic patients who underwent liver transplants for nonalcoholic steatohepatitis (NASH) versus alcoholic liver disease (ETOH) and found no statistically significant differences in post-transplant survival rates between the NASH and ETOH groups

25 Nov 2009

Canadians with chronic neck and back pain now have access to top spinal care

Canadians suffering from chronic and severe neck and back pain now have access to the top spinal care available. Spinal heath expert, Dr. Ron Nusbaum, has launched Back Clinics of Canada, a state-of-the-art facility that focuses on educating patients on the importance of spinal health and offering cutting-edge care that can bring an end to back pain.

25 Nov 2009

NCCN Guidelines adds ofatumumab and romidepsin as therapy options for CLL

Two recent FDA approvals have prompted the National Comprehensive Cancer Network (NCCN) to update the NCCN Clinical Practice Guidelines in Oncology(TM) for Non-Hodgkin's Lymphomas to include ofatumumab (Azerra(TM), GlaxoSmithKline) and romidepsin (Istodax(R), Gloucester Pharmaceuticals) as treatment options for select patients with two types of Non-Hodgkin's Lymphomas.

24 Nov 2009

Researchers find causes for patellofemoral pain syndrome

From professional athletes to weekend warriors, the condition known as "runner's knee" is a painful and potentially debilitating injury suffered by millions of people - although until now, it has been unclear just what causes it.

24 Nov 2009

New computational tool may aid surgeons plan for life-saving pediatric operation

A team of researchers at the University of California, San Diego and Stanford University has developed a way to simulate blood flow on the computer to optimize surgical designs. It is the basis of a new tool that may help surgeons plan for a life-saving operation called the "Fontan" surgery, which is performed on babies born with severe congenital heart defects.

24 Nov 2009

Top-line data from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS to be presented

Lexicon Pharmaceuticals, Inc., announced today that top-line data from its Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) will be presented at GASTRO 2009 in London this week. Results from the study, which showed a significant improvement in IBS symptoms, will be presented by Dr. Philip M. Brown, Lexicon's senior vice president of clinical development, on November 25, 2009 at 2:30 pm local time at the session entitled, "Therapeutic insights in functional digestive disorders."

23 Nov 2009

New Drug Application for ticagrelor submitted to the FDA

AstraZeneca today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS).

23 Nov 2009

Journal highlights debate over collective depression syndrome among asylum-seeking detainees

A new paper by William W Bostock from the School of Government, University of Tasmania, analysing the debate between the psychiatric profession and the Australian government over collective depression syndrome found among asylum-seeking detainees, has been published in the Dove Medical Press journal: Psychology Research and Behavior Management.

23 Nov 2009

Potential therapeutic strategy to improve cognition in Down syndrome identified: DSRTF

The Down Syndrome Research and Treatment Foundation (DSRTF) announces the identification of a new potential therapeutic strategy to address cognitive decline and improve cognition in Down syndrome. The findings were published in Science Translational Medicine on November 18, 2009 by DSRTF-supported researchers, Drs. Ahmad Salehi, William Mobley, and colleagues at Stanford and UCSD Schools of Medicine.

23 Nov 2009

Review of study presented at American Heart Association Scientific Sessions

Adding the cholesterol drug niacin to a statin improved HDL ("good") cholesterol levels and significantly reduced carotid arterial plaque buildup measured with ultrasound within 8 months, with further improvement seen at the end of the study (14 months).

21 Nov 2009

Genetic sonogram improves accuracy of noninvasive prenatal screening and detection of Down syndrome

The addition of a "genetic sonogram" maximizes the accuracy of non-invasive testing for Down syndrome, said a Baylor College of Medicine researcher who was lead author of a landmark study in the current issue of Obstetrics and Gynecology.

21 Nov 2009

NHLBI-supported research shares new strategies on hypertension, heart defect and air pollution

New education strategies for better controlling hypertension and research suggesting a possible link between short-term and long-term exposure to air pollution and increased risk of constricted blood vessels are among the research highlights from studies supported by the National Heart, Lung, and Blood Institute (NHLBI) at the American Heart Association's 2009 Scientific Sessions in Orlando held Nov. 14-18.

20 Nov 2009

Scientists use exome sequencing method to discover the cause of mendelian disorder

For the first time, scientists have successfully used a method called exome sequencing to quickly discover a previously unknown gene responsible for a mendelian disorder.

20 Nov 2009

Pediatric immunologist receives prestigious annual award from American Philosophical Society

A pediatric immunologist at The Children's Hospital of Philadelphia has received a prestigious annual award from the American Philosophical Society, an organization founded in 1743 by Benjamin Franklin. Jordan S. Orange, M.D., Ph.D., received the Society's Judson Daland Prize on Nov. 13 for his contributions to research and treatment of inherited immune deficiency diseases.

20 Nov 2009

Swissmedic grants marketing authorization for Amitiza

Sucampo Pharma Europe Ltd., a subsidiary of Sucampo Pharmaceuticals, Inc., today announced that Swissmedic, the Swiss Agency for Therapeutic Products, has granted a marketing authorization for Amitiza® (lubiprostone) 24 microgram (mcg) gel capsules for the long-term treatment of patients with chronic idiopathic constipation (CIC).

20 Nov 2009

Gastrointestinal symptoms may interfere with nutritional management of ED patients

Eating disorders (ED) patients display a high prevalence of gastrointestinal symptoms and functional gastrointestinal disorders such as irritable bowel syndrome. These symptoms may interfere with their nutritional management. Ingestion of fructose-sorbitol (F-S) is an established means of gastrointestinal symptom provocation in irritable bowel syndrome patients.

20 Nov 2009

Syndrome News and Research

Amgen to present updated data on Nplate at the 2009 ASH meeting

BioMarin Pharmaceutical receives FDA orphan drug designation for 3,4-DAP

Additional data on lubiprostone presented at the GASTRO 2009 UEGF/WCOG meeting

Health watch: When you eat just as vital to what you eat

Comparison study finds no significant differences in post-transplant survival rates of NASH and ETOH groups

Canadians with chronic neck and back pain now have access to top spinal care

NCCN Guidelines adds ofatumumab and romidepsin as therapy options for CLL

Researchers find causes for patellofemoral pain syndrome

New computational tool may aid surgeons plan for life-saving pediatric operation

Top-line data from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS to be presented

New Drug Application for ticagrelor submitted to the FDA

Journal highlights debate over collective depression syndrome among asylum-seeking detainees

Potential therapeutic strategy to improve cognition in Down syndrome identified: DSRTF

Review of study presented at American Heart Association Scientific Sessions

Genetic sonogram improves accuracy of noninvasive prenatal screening and detection of Down syndrome

NHLBI-supported research shares new strategies on hypertension, heart defect and air pollution

Scientists use exome sequencing method to discover the cause of mendelian disorder

Pediatric immunologist receives prestigious annual award from American Philosophical Society

Swissmedic grants marketing authorization for Amitiza

Gastrointestinal symptoms may interfere with nutritional management of ED patients

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News